03:35 AM EDT, 10/29/2026 (MT Newswires) -- RBC Capital Markets revised its model for GSK (GSK.L), updating earnings estimates to account for recent trends and the British drugmaker's third-quarter results. "Overall, we thought the quarter was mixed, the key debate following the 3Q26 call centered on why Q4M pharmacokinetic data for EXTEND, 3x-yearly long-acting injectable HIV PrEP candidate (intramuscular cabotegravir), was not yet disclosed despite being in-house. However, in our follow-up call, management provided a more reassuring explanation. They clarified the timing reflects patient metabolism variability rather than a formulation issue. Specifically, patients took slightly longer to reach steady-state drug levels, with the last patients only recently hitting the month-13+ protocol endpoint," analysts said Wednesday, adding that Cuatro's "different" 11-month virological endpoint offers "no structural read-through." GSK's third-quarter turnover reached 8.89 billion pounds sterling, up 4% on an actual exchange rate basis and 5% at constant currency. Meanwhile, total operating profit dropped to 2.13 billion pounds, down 18% as reported and 16% on a constant-currency basis, weighed down by a restructuring charge under the Accelerate Growth initiative and reduced net other operating income, partly offset by core operating profit growth. As such, the research firm trimmed the sector perform-rated stock's price target to 19.25 pounds from 19.75 pounds. RBC also made cuts to its full-year 2026 to 2028 revenue projections and its diluted operating EPS estimates for the same period. Analysts expect key fourth-quarter catalysts to include the phase 3 Ocean trial readout for Exdensur in eosinophilic granulomatosis with polyangiitis and the phase 2b Q3M data readout for cabotegravir in HIV treatment.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.